Moheb Wadie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Moheb Wadie has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Bendary
Benha University, Benha, Egypt
3 shared publications - Mohamed E. E. Shams
Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy Mansoura University Mansoura Egypt
3 shared publications - Noha Osama Mansour
Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy Mansoura University Mansoura Egypt
3 shared publications - Abdelrahman N. Emara
Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt
2 shared publications - Ahmed Ibrahim Bedier2 shared publications
- Ahmed Shawky Elserafy
Department of Cardiology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
2 shared publications
Latest Publications
- 3 November 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
Dapagliflozin vs. Acetazolamide in Patients With Acute Heart Failure: A Randomized Controlled Trial ( CHOICE ‐ AHF )
Early adjunctive therapies may improve decongestion and symptoms in acute heart failure. This trial compared dapagliflozin with acetazolamide when initiated early, focusing on dyspnea relief as the primary outcome and decongestive, diuretic, natriuretic, and safety outcomes. In this randomized, active‐controlled trial, 108 adults hospitalized with acute heart failure, dyspnea, and objective evidence of congestion requiring intravenous loop diuretics were randomized to receive dapagliflozin 10 mg ( N = 55) or acetazolamide 500 mg ( N = 53) once daily for 3 days alongside standard care. The primary endpoint was the between‐group difference in 72‐hour dyspnea visual analog scale area under the curve. Secondary endpoints included successful decongestion within 3 days, diuretic and natriuretic responses, the relative change in N‐terminal pro‐B‐type natriuretic peptide levels from baseline to day 3, and safety. Acetazolamide produced a significantly lower 72‐hour dyspnea area under the curve than dapagliflozin (2647.9 ± 1213.8 vs. 2988.7 ± 1196.7 mm × hour; P = 0.048). It increased cumulative urine output over 72 hours (12,200 vs. 10,000 mL; P = 0.019) and total natriuresis over 48 hours (824.7 vs. 547.9 mmol; P = 0.001). Dapagliflozin achieved a larger reduction in N‐terminal pro‐B‐type natriuretic peptide at 72 hours (−34.2% vs. −25.0%; P = 0.003). Safety events were infrequent and similar. In conclusion, acetazolamide provided greater dyspnea relief, diuresis, and natriuresis, whereas dapagliflozin produced a larger short‐term reduction in N‐terminal pro‐B‐type natriuretic peptide. Further studies are needed to validate these findings. Trial registration: https://clinicaltrials.gov/study/NCT06783166 .
- 3 November 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
Dapagliflozin vs. Acetazolamide in Patients With Acute Heart Failure: A Randomized Controlled Trial ( CHOICE ‐ AHF )
Early adjunctive therapies may improve decongestion and symptoms in acute heart failure. This trial compared dapagliflozin with acetazolamide when initiated early, focusing on dyspnea relief as the primary outcome and decongestive, diuretic, natriuretic, and safety outcomes. In this randomized, active‐controlled trial, 108 adults hospitalized with acute heart failure, dyspnea, and objective evidence of congestion requiring intravenous loop diuretics were randomized to receive dapagliflozin 10 mg ( N = 55) or acetazolamide 500 mg ( N = 53) once daily for 3 days alongside standard care. The primary endpoint was the between‐group difference in 72‐hour dyspnea visual analog scale area under the curve. Secondary endpoints included successful decongestion within 3 days, diuretic and natriuretic responses, the relative change in N‐terminal pro‐B‐type natriuretic peptide levels from baseline to day 3, and safety. Acetazolamide produced a significantly lower 72‐hour dyspnea area under the curve than dapagliflozin (2647.9 ± 1213.8 vs. 2988.7 ± 1196.7 mm × hour; P = 0.048). It increased cumulative urine output over 72 hours (12,200 vs. 10,000 mL; P = 0.019) and total natriuresis over 48 hours (824.7 vs. 547.9 mmol; P = 0.001). Dapagliflozin achieved a larger reduction in N‐terminal pro‐B‐type natriuretic peptide at 72 hours (−34.2% vs. −25.0%; P = 0.003). Safety events were infrequent and similar. In conclusion, acetazolamide provided greater dyspnea relief, diuresis, and natriuresis, whereas dapagliflozin produced a larger short‐term reduction in N‐terminal pro‐B‐type natriuretic peptide. Further studies are needed to validate these findings. Trial registration: https://clinicaltrials.gov/study/NCT06783166 .
- Open Access
- 30 June 2026
- Published by Pakistan Cardiac Society in Pakistan Heart Journal
- Vol. 59 (3) , 614-620
Predictors of Coronary Artery Disease Severity in Patients with Inflammatory Bowel Disease: A Case-Control Study
Objectives: This study aimed to identify risk factors that may predict the severity of coronary artery disease (CAD) among patients with inflammatory bowel disease (IBD). Methodology: A case-control study was conducted on 110 participants, comprising 55 patients with IBD and 55 healthy controls. Cardiovascular risk was evaluated using the Framingham risk score, carotid intima-media thickness (CIMT), and coronary angiography quantified by the SYNTAX score. CAD severity was categorized as low (SYNTAX ≤22) or moderate-to-high (SYNTAX >22). Results: Patients with IBD exhibited significantly higher leukocyte counts, fasting blood glucose, C-reactive protein (CRP), CIMT, and SYNTAX scores compared to controls (p22, age, diabetes mellitus (DM), hypertension (HTN), smoking, and IBD prevalence were significantly higher. Multivariate logistic regression identified DM (OR=5.26, p=0.022), HTN (OR=3.89, p=0.026), smoking (OR=4.52, p=0.024), and IBD (OR=2.77, p<0.001) as independent predictors of severe CAD. Conclusion: IBD is significantly associated with more severe CAD, reflected in higher SYNTAX scores and CIMT values, independent of traditional cardiovascular risk factors. These findings highlight the importance of incorporating chronic inflammation markers into cardiovascular risk assessment models for IBD patients.
- 30 June 2026
- Published by Pakistan Cardiac Society in Pakistan Heart Journal
- Vol. 59 (3) , 614-620
Open AccessPredictors of Coronary Artery Disease Severity in Patients with Inflammatory Bowel Disease: A Case-Control Study
Objectives: This study aimed to identify risk factors that may predict the severity of coronary artery disease (CAD) among patients with inflammatory bowel disease (IBD). Methodology: A case-control study was conducted on 110 participants, comprising 55 patients with IBD and 55 healthy controls. Cardiovascular risk was evaluated using the Framingham risk score, carotid intima-media thickness (CIMT), and coronary angiography quantified by the SYNTAX score. CAD severity was categorized as low (SYNTAX ≤22) or moderate-to-high (SYNTAX >22). Results: Patients with IBD exhibited significantly higher leukocyte counts, fasting blood glucose, C-reactive protein (CRP), CIMT, and SYNTAX scores compared to controls (p22, age, diabetes mellitus (DM), hypertension (HTN), smoking, and IBD prevalence were significantly higher. Multivariate logistic regression identified DM (OR=5.26, p=0.022), HTN (OR=3.89, p=0.026), smoking (OR=4.52, p=0.024), and IBD (OR=2.77, p<0.001) as independent predictors of severe CAD. Conclusion: IBD is significantly associated with more severe CAD, reflected in higher SYNTAX scores and CIMT values, independent of traditional cardiovascular risk factors. These findings highlight the importance of incorporating chronic inflammation markers into cardiovascular risk assessment models for IBD patients.
- Open Access
- 30 June 2026
- Published by Pakistan Cardiac Society in Pakistan Heart Journal
- Vol. 59 (3) , 700-706
Association of Neutrophil-to-Lymphocyte Ratio with Cardiovascular and Renal Comorbidities in Isolated Systolic Hypertension: A Cross-Sectional Study
Objectives: Isolated systolic hypertension (ISH) is a highly prevalent phenotype of hypertension in older adults and is strongly linked with systemic inflammation. The neutrophil-to-lymphocyte ratio (NLR), an accessible marker derived from complete blood counts, may reflect inflammatory status and predict adverse cardiovascular and renal outcomes. This study aimed to investigate the association between NLR and ISH, and to evaluate its relationship with cardiovascular and renal comorbidities. Methodology: A cross-sectional study was conducted among 300 adults, including 200 ISH patients and 100 age- and sex-matched normotensive controls. Demographic, clinical, and laboratory data were collected. NLR was calculated from absolute neutrophil and lymphocyte counts. Comorbid conditions including cerebrovascular stroke, myocardial infarction (MI), angina, and acute kidney injury (AKI) were identified through clinical assessment and medical records. Statistical analyses included t-tests, chi-square tests, correlation analysis, logistic regression, and ROC curve analysis. Results: Compared to controls, ISH patients had significantly higher WBCs (11.03 ± 3.76 vs. 9.82 ± 2.1 ×10³/μL, p=0.003), neutrophils (6.41 ± 3.29 vs. 3.57 ± 1.49 ×10³/μL, p<0.001), and NLR (3.94 ± 4.27 vs. 1.55 ± 0.83, p<0.001), with lower lymphocytes (2.21 ± 0.91 vs. 2.55 ± 0.8 ×10³/μL, p=0.002). CRP levels were significantly elevated in ISH patients (p<0.001). Cardiovascular and renal comorbidities were more frequent among ISH patients: stroke (38.5% vs. 13%), MI (18.5% vs. 2%), angina (22% vs. 4%), and AKI (33.5% vs. 18%) (all p1.9 (sensitivity 71%, specificity 69%). Conclusion: Elevated NLR is strongly associated with ISH and its cardiovascular and renal comorbidities. As a cost-effective inflammatory marker, NLR may serve as a practical tool for risk stratification in ISH patients.
- 30 June 2026
- Published by Pakistan Cardiac Society in Pakistan Heart Journal
- Vol. 59 (3) , 700-706
Open AccessAssociation of Neutrophil-to-Lymphocyte Ratio with Cardiovascular and Renal Comorbidities in Isolated Systolic Hypertension: A Cross-Sectional Study
Objectives: Isolated systolic hypertension (ISH) is a highly prevalent phenotype of hypertension in older adults and is strongly linked with systemic inflammation. The neutrophil-to-lymphocyte ratio (NLR), an accessible marker derived from complete blood counts, may reflect inflammatory status and predict adverse cardiovascular and renal outcomes. This study aimed to investigate the association between NLR and ISH, and to evaluate its relationship with cardiovascular and renal comorbidities. Methodology: A cross-sectional study was conducted among 300 adults, including 200 ISH patients and 100 age- and sex-matched normotensive controls. Demographic, clinical, and laboratory data were collected. NLR was calculated from absolute neutrophil and lymphocyte counts. Comorbid conditions including cerebrovascular stroke, myocardial infarction (MI), angina, and acute kidney injury (AKI) were identified through clinical assessment and medical records. Statistical analyses included t-tests, chi-square tests, correlation analysis, logistic regression, and ROC curve analysis. Results: Compared to controls, ISH patients had significantly higher WBCs (11.03 ± 3.76 vs. 9.82 ± 2.1 ×10³/μL, p=0.003), neutrophils (6.41 ± 3.29 vs. 3.57 ± 1.49 ×10³/μL, p<0.001), and NLR (3.94 ± 4.27 vs. 1.55 ± 0.83, p<0.001), with lower lymphocytes (2.21 ± 0.91 vs. 2.55 ± 0.8 ×10³/μL, p=0.002). CRP levels were significantly elevated in ISH patients (p<0.001). Cardiovascular and renal comorbidities were more frequent among ISH patients: stroke (38.5% vs. 13%), MI (18.5% vs. 2%), angina (22% vs. 4%), and AKI (33.5% vs. 18%) (all p1.9 (sensitivity 71%, specificity 69%). Conclusion: Elevated NLR is strongly associated with ISH and its cardiovascular and renal comorbidities. As a cost-effective inflammatory marker, NLR may serve as a practical tool for risk stratification in ISH patients.
- Open Access
- 2 October 2025
- Published by Pakistan Cardiac Society in Pakistan Heart Journal
- Vol. 58 (3) , 315-320
Electrocardiographic Characteristics in Angiographically Documented Occlusion of the Left Circumflex Artery with Acute Inferior Myocardial Infarction
Objectives: This study aims to identify specific electrocardiographic (ECG) indicators of left circumflex artery (LCX) occlusion in acute inferior myocardial infarction (MI), thereby improving diagnostic accuracy. Methodology: This prospective study was conducted at Mansoura University Hospital on 50 patients with angiographically confirmed acute inferior MI. Patients with ST-segment elevation in inferior leads and LCX as the infarct-related artery were included. Demographic data, clinical characteristics, and ECG findings were documented, and ST-segment elevation patterns were analyzed to evaluate their sensitivity and specificity in predicting LCX involvement. Results: Among the 50 patients, 67.5% of those with LCX occlusion exhibited greater ST-segment elevation in lead II compared to lead III, whereas this pattern was observed in only 30% of patients with right coronary artery (RCA) occlusion (p = 0.03). This criterion demonstrated a sensitivity of 84.85% and specificity of 93.94% for detecting LCX occlusion. Additionally, ST-segment depression in lead aVR was present in 32.5% of LCX cases versus 70% in RCA cases. The mean age was 56.84 ± 9.71 years for the LCX group and 54.67 ± 12.4 years for the RCA group, with comparable rates of comorbidities. No significant differences were observed in mortality rates (7.5% LCX vs. 10% RCA) or major cardiac events (20% in both groups). Conclusion: ST-segment elevation in lead II exceeding that in lead III serves as a reliable ECG indicator for identifying LCX as the culprit artery in acute inferior MI. This finding provides a valuable tool for prompt and accurate diagnosis.
- 2 October 2025
- Published by Pakistan Cardiac Society in Pakistan Heart Journal
- Vol. 58 (3) , 315-320
Open AccessElectrocardiographic Characteristics in Angiographically Documented Occlusion of the Left Circumflex Artery with Acute Inferior Myocardial Infarction
Objectives: This study aims to identify specific electrocardiographic (ECG) indicators of left circumflex artery (LCX) occlusion in acute inferior myocardial infarction (MI), thereby improving diagnostic accuracy. Methodology: This prospective study was conducted at Mansoura University Hospital on 50 patients with angiographically confirmed acute inferior MI. Patients with ST-segment elevation in inferior leads and LCX as the infarct-related artery were included. Demographic data, clinical characteristics, and ECG findings were documented, and ST-segment elevation patterns were analyzed to evaluate their sensitivity and specificity in predicting LCX involvement. Results: Among the 50 patients, 67.5% of those with LCX occlusion exhibited greater ST-segment elevation in lead II compared to lead III, whereas this pattern was observed in only 30% of patients with right coronary artery (RCA) occlusion (p = 0.03). This criterion demonstrated a sensitivity of 84.85% and specificity of 93.94% for detecting LCX occlusion. Additionally, ST-segment depression in lead aVR was present in 32.5% of LCX cases versus 70% in RCA cases. The mean age was 56.84 ± 9.71 years for the LCX group and 54.67 ± 12.4 years for the RCA group, with comparable rates of comorbidities. No significant differences were observed in mortality rates (7.5% LCX vs. 10% RCA) or major cardiac events (20% in both groups). Conclusion: ST-segment elevation in lead II exceeding that in lead III serves as a reliable ECG indicator for identifying LCX as the culprit artery in acute inferior MI. This finding provides a valuable tool for prompt and accurate diagnosis.
- Open Access
- 25 October 2024
- Published by Springer Nature in Cardiology and Therapy
- Vol. 13 (4) , 707-736
ACE Inhibitors and Angiotensin Receptor Blockers for the Primary and Secondary Prevention of Cardiovascular Outcomes: Recommendations from the 2024 Egyptian Cardiology Expert Consensus in Collaboration with the CVREP Foundation
Introduction The renin–angiotensin–aldosterone system (RAAS) plays a pivotal role in regulating blood pressure (BP), with dysregulation of RAAS resulting in hypertension and potentially heart failure (HF), myocardial infarction (MI), cardio-renal syndrome, and stroke. RAAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs), have advantages beyond BP control. However, differences between these two drug classes need to be considered when choosing a therapy for preventing cardiovascular events. Methods A panel of 36 Egyptian cardiologists developed consensus statements on RAAS inhibitors for primary and secondary prevention of cardiovascular outcomes and stroke, using a modified three-step Delphi process. Results The consensus statements highlight the importance of effective BP control and the role of RAAS blockade for prevention and management of various cardiovascular diseases. ACEis and ARBs differ in their mode of action and, thus, clinical effects. On the basis of available evidence, the consensus group recommended the following: ACEis should be considered as first choice (in preference to ARBs) to reduce the risk of MI, for primary prevention of HF, and for secondary prevention of stroke. ACEis and ARBs show equivalent efficacy for the primary prevention of stroke. Evidence also favors the preferential use of ACEis in patients with type 2 diabetes, for BP control, for the primary prevention of diabetic kidney disease, and to reduce the risk of major cardiovascular and renal outcomes. Treatment with an ACEi should be started within 24 h of ST segment elevation MI (and continued long term) in patients with HF, left ventricular systolic dysfunction, and/or diabetes. Angiotensin receptor/neprilysin inhibitors (ARNIs) are the first choice for patients with HF and reduced ejection fraction, with ACEis being the second choice in this group. ARBs are indicated as alternatives in patients who cannot tolerate ACEis. ACEis may be associated with cough development, but the incidence tends to be overestimated, and the risk can be reduced by use of a lipophilic ACEi or combining the ACEi with a calcium channel blocker. Conclusion RAAS blockade is an essential component of hypertension therapy; however, the protective effects provided by ACEis are superior to those of ARBs. Therefore, an ACEi is indicated in almost all cases, unless not tolerated.
- 25 October 2024
- Published by Springer Nature in Cardiology and Therapy
- Vol. 13 (4) , 707-736
Open AccessACE Inhibitors and Angiotensin Receptor Blockers for the Primary and Secondary Prevention of Cardiovascular Outcomes: Recommendations from the 2024 Egyptian Cardiology Expert Consensus in Collaboration with the CVREP Foundation
Introduction The renin–angiotensin–aldosterone system (RAAS) plays a pivotal role in regulating blood pressure (BP), with dysregulation of RAAS resulting in hypertension and potentially heart failure (HF), myocardial infarction (MI), cardio-renal syndrome, and stroke. RAAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs), have advantages beyond BP control. However, differences between these two drug classes need to be considered when choosing a therapy for preventing cardiovascular events. Methods A panel of 36 Egyptian cardiologists developed consensus statements on RAAS inhibitors for primary and secondary prevention of cardiovascular outcomes and stroke, using a modified three-step Delphi process. Results The consensus statements highlight the importance of effective BP control and the role of RAAS blockade for prevention and management of various cardiovascular diseases. ACEis and ARBs differ in their mode of action and, thus, clinical effects. On the basis of available evidence, the consensus group recommended the following: ACEis should be considered as first choice (in preference to ARBs) to reduce the risk of MI, for primary prevention of HF, and for secondary prevention of stroke. ACEis and ARBs show equivalent efficacy for the primary prevention of stroke. Evidence also favors the preferential use of ACEis in patients with type 2 diabetes, for BP control, for the primary prevention of diabetic kidney disease, and to reduce the risk of major cardiovascular and renal outcomes. Treatment with an ACEi should be started within 24 h of ST segment elevation MI (and continued long term) in patients with HF, left ventricular systolic dysfunction, and/or diabetes. Angiotensin receptor/neprilysin inhibitors (ARNIs) are the first choice for patients with HF and reduced ejection fraction, with ACEis being the second choice in this group. ARBs are indicated as alternatives in patients who cannot tolerate ACEis. ACEis may be associated with cough development, but the incidence tends to be overestimated, and the risk can be reduced by use of a lipophilic ACEi or combining the ACEi with a calcium channel blocker. Conclusion RAAS blockade is an essential component of hypertension therapy; however, the protective effects provided by ACEis are superior to those of ARBs. Therefore, an ACEi is indicated in almost all cases, unless not tolerated.
- 1 November 2023
- Published by Elsevier in European Journal of Pharmacology
- Vol. 961, 176179
The clinical outcomes of dapagliflozin in patients with acute heart failure: A randomized controlled trial (DAPA-RESPONSE-AHF)
- 1 November 2023
- Published by Elsevier in European Journal of Pharmacology
- Vol. 961, 176179
The clinical outcomes of dapagliflozin in patients with acute heart failure: A randomized controlled trial (DAPA-RESPONSE-AHF)
- Open Access
- 28 April 2023
- Published by Springer Nature in Research Square
Value of global longitudinal peak systolic strain derived by 2-D speckle tracking in detection of obstructive coronary artery disease
Background: Early detection of obstructive coronary artery disease (CAD) using Peak Systolic global longitudinal strain derived by 2-D Speckle Tracking in patients with chronic stable angina. 75 patients with chronic stable angina were enrolled in this cross sectional study, (Mean age was 56.69 ± 6.96 y, 35 were males), 42.7 % were diabetic and all patients were assessed by thorough history taking, clinical examination,12 lead surface ECG, conventional, speckle Echocardiography and coronary angiography in Mansoura specialized medical hospital from march 2017 to October 2017 Results: Statistically significant decrease was found in GLS-Avg values in patients with obstructive CAD when compared to patients with normal coronary angiography (pConclusion: longitudinal strain derived by speckle tracking can be used as non-invasive simple test for evaluation of patients with chronic stable angina and as a predictor for presence or absence of obstructive CAD
- 28 April 2023
- Published by Springer Nature in Research Square
Open AccessValue of global longitudinal peak systolic strain derived by 2-D speckle tracking in detection of obstructive coronary artery disease
Background: Early detection of obstructive coronary artery disease (CAD) using Peak Systolic global longitudinal strain derived by 2-D Speckle Tracking in patients with chronic stable angina. 75 patients with chronic stable angina were enrolled in this cross sectional study, (Mean age was 56.69 ± 6.96 y, 35 were males), 42.7 % were diabetic and all patients were assessed by thorough history taking, clinical examination,12 lead surface ECG, conventional, speckle Echocardiography and coronary angiography in Mansoura specialized medical hospital from march 2017 to October 2017 Results: Statistically significant decrease was found in GLS-Avg values in patients with obstructive CAD when compared to patients with normal coronary angiography (pConclusion: longitudinal strain derived by speckle tracking can be used as non-invasive simple test for evaluation of patients with chronic stable angina and as a predictor for presence or absence of obstructive CAD
- Open Access
- 31 May 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (11) , 3112
Efficacy of Nondiuretic Pharmacotherapy for Improving the Treatment of Congestion in Patients with Acute Heart Failure: A Systematic Review of Randomised Controlled Trials
Diuretic therapy is the mainstay during episodes of acute heart failure (AHF). Diuretic resistance is often encountered and poses a substantial challenge for clinicians. There is a lack of evidence on the optimal strategies to tackle this problem. This review aimed to compare the outcomes associated with congestion management based on a strategy of pharmacological nondiuretic-based regimens. The PubMed, Cochrane Library, Scopus, and ScienceDirect databases were systematically searched for all randomised controlled trials (RCTs) of adjuvant pharmacological treatments used during hospitalisation episodes of AHF patients. Congestion relief constitutes the main target in AHF; hence, only studies with efficacy indicators related to decongestion enhancement were included. The Cochrane risk-of-bias tool was used to evaluate the methodological quality of the included RCTs. Twenty-three studies were included; dyspnea relief constituted the critical efficacy endpoint in most included studies. However, substantial variations in dyspnea measurement were found. Tolvaptan and serelaxin were found to be promising options that might improve decongestion in AHF patients. However, further high-quality RCTs using a standardised approach to diuretic management, including dosing and monitoring strategies, are crucial to provide new insights and recommendations for managing heart failure in acute settings.
- 31 May 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (11) , 3112
Open AccessEfficacy of Nondiuretic Pharmacotherapy for Improving the Treatment of Congestion in Patients with Acute Heart Failure: A Systematic Review of Randomised Controlled Trials
Diuretic therapy is the mainstay during episodes of acute heart failure (AHF). Diuretic resistance is often encountered and poses a substantial challenge for clinicians. There is a lack of evidence on the optimal strategies to tackle this problem. This review aimed to compare the outcomes associated with congestion management based on a strategy of pharmacological nondiuretic-based regimens. The PubMed, Cochrane Library, Scopus, and ScienceDirect databases were systematically searched for all randomised controlled trials (RCTs) of adjuvant pharmacological treatments used during hospitalisation episodes of AHF patients. Congestion relief constitutes the main target in AHF; hence, only studies with efficacy indicators related to decongestion enhancement were included. The Cochrane risk-of-bias tool was used to evaluate the methodological quality of the included RCTs. Twenty-three studies were included; dyspnea relief constituted the critical efficacy endpoint in most included studies. However, substantial variations in dyspnea measurement were found. Tolvaptan and serelaxin were found to be promising options that might improve decongestion in AHF patients. However, further high-quality RCTs using a standardised approach to diuretic management, including dosing and monitoring strategies, are crucial to provide new insights and recommendations for managing heart failure in acute settings.
- Open Access
- 1 December 2021
- Published by Mansoura University in Mansoura Medical Journal
- Vol. 50 (4) , 184-202
Myocardial infarction in COVID-19 era
A lot of people were affected with COVID-19, and it has an obvious effect on the heart. There are many cardiovascular complications of corona virus disease. Myocardial infarction is one of the diseases that can be caused by this virus and it is common among those patients. As well as, echocardiographic changes are found in COVID-19 patients like ST elevation that may resemble that of MI. However, the incidence of MI decreased during this pandemic due to many causes including the fear of the patients from catching the infection from the hospitals. In addition to that, there are many mechanisms that can lead to MI in those patients, including cytokine storm. Elevated cardiac troponin in COVID-19 patients may indicate type 2 MI or type 1 but it has a prognostic value. The management didn’t change a lot during the pandemic in comparison to before it, however personal protective equipment is very important to protect the medical stuff from the virus.
- 1 December 2021
- Published by Mansoura University in Mansoura Medical Journal
- Vol. 50 (4) , 184-202
Open AccessMyocardial infarction in COVID-19 era
A lot of people were affected with COVID-19, and it has an obvious effect on the heart. There are many cardiovascular complications of corona virus disease. Myocardial infarction is one of the diseases that can be caused by this virus and it is common among those patients. As well as, echocardiographic changes are found in COVID-19 patients like ST elevation that may resemble that of MI. However, the incidence of MI decreased during this pandemic due to many causes including the fear of the patients from catching the infection from the hospitals. In addition to that, there are many mechanisms that can lead to MI in those patients, including cytokine storm. Elevated cardiac troponin in COVID-19 patients may indicate type 2 MI or type 1 but it has a prognostic value. The management didn’t change a lot during the pandemic in comparison to before it, however personal protective equipment is very important to protect the medical stuff from the virus.
- Open Access
- 1 October 2021
- Published by Oxford University Press (OUP) in European Heart Journal Supplements
- Vol. 23 (Supplement)
Estimated Prevalence of Familial Hypercholesterolemia Among Egyptian Patients with Acute Coronary Syndromes; Analysis from The Cardiorisk Project
Aims: The prevalence of familial hypercholesterolemia (FH) in Egypt is largely un- known. We aimed to estimate the prevalence of FH among 3224 Egyptian patients with acute coronary syndromes enrolled from 2015 to 2018 in the nationwide cross- sectional cardioRisk project. Methods and Results: We applied the Dutch Lipid Clinic criteria for the diagnosis of FH on the available data recorded for the patients enrolled in the CardioRisk project. Two main criteria were applied: the presence of premature CAD (given 2 points in the Dutch criteria), and the categorized low density lipoprotein cholesterol (LDL-C) lev- els (given 1, 3, 5, or 8 points in the Dutch criteria according to the level). From a total of 3224 patients, 2743 patients had available LDL-C levels. Among those patients, when applying the abovementioned 2 criteria, we estimated that 472 patients had at least ‘possible’ FH (17.2% of the total population). Specifically, 4 patients had ‘defi- nite’ FH (0.1%), 7 patients had ‘probable’ FH (0.25%), and 461 patients had ‘possi- ble’ FH (16.8%). Conclusion: The estimated prevalence of at least ‘possible’ FH among Egyptian patients with ACS is 17%.
- 1 October 2021
- Published by Oxford University Press (OUP) in European Heart Journal Supplements
- Vol. 23 (Supplement)
Open AccessEstimated Prevalence of Familial Hypercholesterolemia Among Egyptian Patients with Acute Coronary Syndromes; Analysis from The Cardiorisk Project
Aims: The prevalence of familial hypercholesterolemia (FH) in Egypt is largely un- known. We aimed to estimate the prevalence of FH among 3224 Egyptian patients with acute coronary syndromes enrolled from 2015 to 2018 in the nationwide cross- sectional cardioRisk project. Methods and Results: We applied the Dutch Lipid Clinic criteria for the diagnosis of FH on the available data recorded for the patients enrolled in the CardioRisk project. Two main criteria were applied: the presence of premature CAD (given 2 points in the Dutch criteria), and the categorized low density lipoprotein cholesterol (LDL-C) lev- els (given 1, 3, 5, or 8 points in the Dutch criteria according to the level). From a total of 3224 patients, 2743 patients had available LDL-C levels. Among those patients, when applying the abovementioned 2 criteria, we estimated that 472 patients had at least ‘possible’ FH (17.2% of the total population). Specifically, 4 patients had ‘defi- nite’ FH (0.1%), 7 patients had ‘probable’ FH (0.25%), and 461 patients had ‘possi- ble’ FH (16.8%). Conclusion: The estimated prevalence of at least ‘possible’ FH among Egyptian patients with ACS is 17%.